News
Biologicals sales have almost doubled since 2006
2013-09-30 Sales of biologicals have almost doubled from US$63.8 billion in 2006 to US$124.6 billion in 2012. During this time period, the best selling therapeutic classes… Read More »
Use of G-CSF biosimilars for stem cell mobilization in autologous transplantation
2013-09-27 The first biosimilar granulocyte colony-stimulating factor (G-CSF) was licensed by EMA in 2008, and there are currently six biosimilar G-CSF products licensed for use in… Read More »
Positive post-marketing data for biosimilar epoetin
2013-09-25 Injectable generics specialist, Hospira, presented results from a post-marketing study of the company’s European biosimilar epoetin (Retacrit) on 3 June 2013 at the 48th Annual… Read More »
Biopharmaceutical products in Iran
2013-09-23 Iran will become a leader in biotechnology products (especially copied biopharmaceuticals) in Asia over the next three years, according to a review by Mahboudi et… Read More »
Equivalence of generic immunosuppressants
2013-09-20 There are no compelling pharmacological arguments against the sensible use of the generic immunosuppressants ciclosporin, tacrolimus and mycophenolate mofetil in clinical practice, argue pharmacologists working… Read More »
Use of G-CSF biosimilars for stem cell mobilization in healthy donors
2013-09-18 Granulocyte colony-stimulating factor (G-CSF) can be used to mobilize peripheral blood stem cells (PBSCs) in healthy donors. Over the last 10 years, the procedure has… Read More »
Kazakhstan, Russia, Ukraine to change drug reimbursement schemes
2013-09-16 Most of the Commonwealth of Independent States (CIS) countries do not have modern drug reimbursement policies. However, recently Kazakhstan, Russia and Ukraine have all taken… Read More »
Biosimilars and US exclusivity
2013-09-13 Currently, the legal pathway in the US for the approval of biosimilars is the Biologics Price Competition and Innovation Act (BPCI Act) of 2009. The… Read More »
The biggest drug patent losses for 2013
2013-09-11 During 2012–2018 over US$290 billion of sales are at risk from patent expirations. In fact, in 2013 alone patents will expire on drugs with yearly… Read More »
Innovation in the generics industry
2013-09-09 The decrease in innovation in the originator pharmaceutical industry is leading to an increase in innovation in the generics pharmaceutical industry, according to new research.… Read More »
